About Coley Pharmaceutical
Coley Pharmaceutical is a Healthcare company based in Wellesley (United States) founded in 1997, and was acquired by Pfizer in November 2007. Immunomodulatory drugs and vaccine adjuvants targeting TLRs were developed. Coley Pharmaceutical has raised $55 million across 2 funding rounds from investors including Pfizer, Thomas, McNerney & Partners and Venrock. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Immunotherapy and Vaccine. Its competitors include Emergent BioSolutions, Adjuvance Technologies and Kineta; 2 of its 3 listed competitors have raised funding.
Company details
Coley Pharmaceutical was founded in 1997 in Wellesley, United States, within the biotechnology sector. Focus was placed on developing immunomodulatory drugs that targeted Toll-like Receptors (TLR) 7, 8, and 9 as immune modulators. These candidates were tested across areas including cancer, asthma, Alzheimers disease, and infectious diseases. Vaccine adjuvants were also developed and commercialized. Acquisition by Pfizer occurred in November 2007 for 164 million.
- Headquarters Wellesley, United States
- Stage Acquired
- SectorsHealthcare
- Website coleypharma.com
- Social LinkedIn
- Acquired by Pfizer (Nov 2007)
Funding Insights of Coley Pharmaceutical
Coley Pharmaceutical has successfully raised a total of $55M across 2 strategic funding rounds. The most recent funding activity was a Series F round of $25 million completed in September 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $55M
- Total Rounds 2
- Last Round Series F — $25M
- First Round $30M
(Aug 2003)
- Investors Count 4
All 2 funding rounds of Coley Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2004 | $25M | Series F | – | – | |
| Aug 2003 | $30M | Series E | – | – |
5 investors in total: 5 institutional.
Investors in Coley Pharmaceutical
Coley Pharmaceutical has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Thomas, McNerney & Partners and Venrock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| tm-partners.com | ||||
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Early & late stage life sciences focused VC firm funding companies in the US and Europe | global-life-science-ventures.com | Munich, Germany | ||
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for Coley Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Coley Pharmaceutical
5 dated milestones of Coley Pharmaceutical across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Coley Pharmaceutical is founded.
- Funding First funding round of $30.0M.
- Funding Latest funding round, Series F, of $25.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Pfizer.
Competitors of Coley Pharmaceutical
Coley Pharmaceutical has 3 listed competitors in our database, 2 of them funded. They include Emergent BioSolutions, Adjuvance Technologies and Kineta.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| emergentbiosolutions.com | 1998 | Gaithersburg, United States | 1 | Vaccines for viral infections are developed by the company. | ||
| adjuvancetechnologies.com | 2009 | New York, United States | $13.37M | 20 | Vaccine adjuvants are designed and manufactured for medical applications. | |
| kinetabio.com | 2008 | Seattle, United States | $103.53M | 12 | Immune-modulating therapeutics are developed for autoimmune and infectious diseases. |
Detailed competitors of Coley Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Coley Pharmaceutical
Websites that share an audience with Coley Pharmaceutical (coleypharma.com).
Websites whose visitors overlap most with Coley Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| gangagen.com | 100% | 5.2K | #3,829,843 | View details | |
| aegera.com | 100% | View details | |||
| dnagenotek.com | 100% | 18.6K | #1,426,687 | View details | |
| epocal.com | 100% | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Coley Pharmaceutical (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Coley Pharmaceutical
Coley Pharmaceutical was founded in 1997 and raised its 1st funding round 6 years after it was founded.
Coley Pharmaceutical is headquartered in Wellesley, United States. It is registered at Wellesley, Massachusetts, United States.
Coley Pharmaceutical is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a Series E of $30M, raised on Aug 2003.
Coley Pharmaceutical was founded in 1997 in Wellesley, United States, within the biotechnology sector. Focus was placed on developing immunomodulatory drugs that targeted Toll-like Receptors (TLR) 7, 8, and 9 as immune modulators. These candidates were tested across areas including cancer, asthma, Alzheimers disease, and infectious diseases. Vaccine adjuvants were also developed and commercialized. Acquisition by Pfizer occurred in November 2007 for 164 million.
Coley Pharmaceutical's top competitors include Adjuvance Technologies, Emergent BioSolutions and Kineta.
Coley Pharmaceutical has 5 investors. Key investors include Pfizer, Thomas, McNerney & Partners, Venrock, Global Life Science Ventures, and TVM Capital Life Science.
Yes. Coley Pharmaceutical was acquired by Pfizer in November 2007.